MedTrace Logo

Efficacy and Safety of Donepezil Hydrochloride (Aricept) in Vascular Dementia

NCT00165763 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 36

Last updated 2012-05-04

No results posted yet for this study

Summary

The purpose of this study is to examine the efficacy and safety of cholinesterase inhibitor (donepezil hydrochloride) Aricept in patients with vascular dementia (VaD).

Conditions

  • Vascular Dementia

Interventions

DRUG

donepezil hydrochloride (Aricept)

5 mg donepezil HCl given once a day and increased to 10 mg per day if side effects, when present, are tolerated.

Sponsors & Collaborators

  • Eisai Co., Ltd.

    collaborator INDUSTRY

  • Eisai Inc.

    lead INDUSTRY

Principal Investigators

  • Jacqueline Dominguez · Memory Center, St. Luke's Medical Center

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
40 Years
Max Age
60 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2005-09-30
Primary Completion
2009-09-30

Countries

  • Philippines

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00165763 on ClinicalTrials.gov